Clinical Sequencing
News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
In Brief This Week: 23andMe, OS Therapies, Zai Lab, Genetic Alliance, Galatea Bio, Mursla Bio
News items for the week of April 21, 2025.
Invivoscribe's LabPMM Nabs NY State Approval for MRD Assay
The company can now offer the FLT3 ITD MRD Assay in New York state to assess measurable residual disease to guide treatment for acute myeloid leukemia patients.
Adaptive Biotechnologies Wins Expanded Medicare Coverage of ClonoSeq in Mantle Cell Lymphoma
The expanded coverage adds to the existing Medicare payment structure for ClonoSeq, which provides coverage for a bundle of tests to assess patient therapy response.
Pillar Biosciences Receives CMS Coverage for Pan-Cancer CDx Assay
The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.
OncoHelix, AstraZeneca Canada Partner to Provide Prostate Cancer Liquid Biopsy Testing
The Canadian lab will assay patients' blood samples using a test developed by Memorial Sloan Kettering and commercialized as a kit in partnership with Sophia Genetics.